Jefferies Downgrades AcelRx Pharmaceuticals To Hold

Analysts at Jefferies downgraded AcelRx Pharmaceuticals, Inc. ACRX from Buy to Hold. The price target for AcelRx Pharmaceuticals has been lowered from $12.00 to $6.00. AcelRx Pharmaceuticals shares have dropped 53.70% over the past 52 weeks, while the S&P 500 index has surged 11.34% in the same period. AcelRx Pharmaceuticals' shares fell 0.91% to $5.46 in after-hours trading.